Cite

    Anastasopoulou, E., Tzonis, P., Fortis, S., Mahaira, L., Vaxevanis, C., Ardavanis, A., Mittendorf, E., Peoples, G., Baxevanis, C., Papamichail, M., & Perez, S. (2015). dRB1*11 allele expression and HER2 pre-existing immunity may predict benefit in breast cancer patients vaccinated with the HER2 modified AE37 peptide vaccine. Journal for immunotherapy of cancer, 3(2), 1–2. http://access.bl.uk/ark:/81055/vdc_100080441580.0x000360